Sulfamethoxazole and dapsone share the same sulphonamide ring with similar antibacterial effects. Detailed studies of dapsone show extensive effects on the immune system with the reduced generation of oxygen free radicals (ROS) and inhibition of neutrophil (NF) myeloperoxidase. These effects reduce intra and extracellular ROS reducing endothelial damage, lipid peroxidation and apoptosis. The bacterial peptide N-formylmet-leu-phe (fMLP) activates the NF via its formyl peptide receptor (FPR) generating ROS much of which is extracellular. The FPR receptor also induces cell migration, granule secretion and lysosomal activation. Dapsone very significantly reduces fMLP activation of NF, giving anti-inflammatory effects. Interestingly phorbol 12-myristate 13-acetate (PMA), a well characterised activator of protein kinase C is less inhibited by dapsone. There are no comparable studies with cotrimoxazole despite its structural similarity. UK clinical studies of cotrimoxazole in Idiopathic pulmonary fibrosis (IPF), suggest protection against sudden severe exacerbations. Cotrimoxazole is thought to act via its anti-bacterial properties with data showing pathogen carriage in a third of new IPF cases. Oxidative stress is increased in IPF and limited studies show that peripheral monocyte (MF) depletion via a charcoal column in IPF exacerbations has reduced the 30 day mortality. In fibrotic organ injury, recruitment of MF appears critical and blocking MF activation and recruitment arrests the fibrotic process. We have examined by flow cytometry the effects of oral cotrimoxazole upon NF and MF activation in IPF patients on long-term treatment and healthy controls at baseline and after 1 week of cotrimoxazole. The commercial kit PHAGOBURST (Glycotope Biotechnology) was used, which allows quantitative determination of leucocyte oxidative burst in whole blood following stimulation by opsonized E Coli, PMA and fMLP. Findings Despite the small numbers to date, similar to dapsone there is a significant blocking of oxidative burst to fMLP in NF and MF pre-and post cotrimoxazole with a similar trend in IPF. There is also some reduction in PMA oxidative burst, but none to E.coli. The reduced MF stimulation may reflect the lower MF bloods counts. If NF and MF ROS generation are reduced by cotrimoxazole, this may stabilise the disease process protecting against severe exacerbations.
Introduction Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial lung disease, with a poor prognosis and a lack of therapeutic options that halt disease progression. While the aetiology of IPF is unknown, dysregulated epithelial and mesenchymal response following persistent epithelial insult is thought to be critical in driving fibrosis. Recent evidence suggests that, akin to cancer, metabolic reprogramming may be important in driving many of these processes. In both cancer and fibrosis development, inducible expression of the pyruvate kinase isoform M2 (PKM2) represents an important adaptation for increasing the availability of glycolytic intermediates for biosynthesis and cell proliferation. Aim We aim to investigate the expression of PKM2 in relation to cell-specific markers in the IPF lung.
Abstract P49 Table 1 Introduction Type 2 cytokines such as IL-5, IL-13 and IL-4 produced by primed type 2 T cells have been shown to be important in the pathogenesis of eosinophilic airway inflammation. Factors regulating the state of activation of these cells are incompletely understood. We and others have shown that release of IL-13 by stimulated T cells can be inhibited by epithelial cells. This study used a PBMC based bulk culture system to: 1) determine whether production of other type-2 cytokines is inhibited by co-culture with epithelial cells; 2) compare inhibition of activated PBMC and human lung lymphocytes and 3) investigate whether specific soluble mediators modified inhibition of IL-13 release. PBMC isolated from blood and lymphocytes isolated from lung tissue were cultured with IL-2 for five days in the absence and presence of A549 and BEAS2B epithelial cells. The cytokines IL-13, IL-5, IL-9 and TNFa were measured in the supernatant of these cells. Similar co-culture experiments were performed in the presence of different inhibitors or blocking cytokine antibodies.
Results Production of all cytokines measured were reduced in the presence of epithelial cells: IL-13 shown as mean pg/10 6 cells+/-SD in 200 U/ml IL-2) PBMC: 1184+/-24,+A549 12 +/-1 or lung cells 795+/-158,+A549 50+/-2. PBMC and lung cells were inhibited to a similar degree although, importantly, lung cells produced more IL-9 and less TNFa than a comparable number of PBMC. We found that adding inhibitors to IL-10, TGF-b, Aryl Hydrocarbon Receptor (AHR blocked with CH-223191), prostaglandins (indomethacin) and nitric oxide (NMMA) did not alter the A549 mediated regulation of IL-13 release by the PBMC or lung cells. Conclusions The inhibition of cytokine release by PBMC and lung cells in the presence of epithelial cells could indicate generalised regulation of inflammatory cytokine release. Blocking of IL-10, TGF-b, AHR, prostaglandins and nitric oxide was not able to reduce the regulation of the cytokine release but more specific inhibitors or further titration may be required. 10.1136/thoraxjnl-2017-210983.194 Rationale and Hypothesis HIV-1-seropositive individuals receiving highly active antiretroviral therapy (HAART) have an increased incidence of chronic obstructive pulmonary disease (COPD), independent of smoking history. Although HIV-1 infection is associated with impaired redox homeostasis and increased pro-inflammatory cytokine expression in the lungs despite HAART, the mechanisms driving HIV-1-associated COPD are poorly understood. Free HIV-1 envelope glycoprotein gp120 is detectable in bronchoalveolar lavage fluid from HAART-treated individuals. gp120 displays affinity (tropism) for either CCR5 or CXCR4 chemokine receptors, and has been implicated as a mediator of inflammation and oxidative stress in various HIV-1-associated disease processes. We hypothesised that gp120 directly induces bronchial epithelial cell oxidative stress, and drives airway inflammation indirectly via alveolar macrophages, a response which is augmented following secondary exposure to pro-inflammatory stimuli such as bacterial pathogens.
Objectives To explore the mechanisms and consequences of gp120 interactions with bronchial epithelial cells and macrophages.
Methods An immortalised bronchial epithelial cell line (BEAS-2B), primary bronchial epithelial cells (PBECs) or monocytederived macrophages (MDMs) from healthy volunteers were treated with recombinant gp120 (CCR5-or CXCR4-tropic, 100 ng/mL) for 24-48 hour. BEAS-2B were primed (or not) with IL-1b. MDMs were co-cultured with confluent BEAS-2B cells at a ratio of 1:5 in the presence or absence of LPS (100 ng/ml). Cytokine outputs were quantified by ELISA, and cellular reactive oxygen species (ROS) production assessed by confocal microscopy using CellROX or MitoSOX reagents. Findings Picomolar concentrations of CXCR4-but not CCR5-tropic gp120 induced CXCL8 release from IL-1b-primed BEAS-2B monocultures and upregulated cellular ROS production in both BEAS-2Bs and PBECs, consistent with expression of CXCR4 but not CCR5 on these cells. gp120 stimulation of BEAS-2B/MDM co-cultures caused no detectable changes in cytokine release. However, co-cultures primed with gp120 (of either tropism) and stimulated with LPS demonstrated significant CXCL8 release at 48 hours, reflecting MDM expression of both chemokine receptors. Impaired redox homeostasis and upregulated inflammatory responses may contribute to gp120-mediated airway epithelial dysfunction, and may drive neutrophil recruitment in this setting.
